Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06189963 · ClinicalTrials.gov registry record · Phase 1
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
A Phase 1 study of Moderate Alzheimer Disease, sponsored by NKGen Biotech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 5
- Study locations
NCT06189963: Recruiting Phase 1 study of Moderate Alzheimer Disease, sponsored by NKGen Biotech.
NCT06189963 is a Phase 1 study of Moderate Alzheimer Disease that is actively recruiting participants, run by NKGen Biotech. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06189963, a Phase 1 study of Moderate Alzheimer Disease, is actively recruiting participants, sponsored by NKGen Biotech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion 2. Can SNK01 administration improve cognitive assessment scores and biomarkers
Primary Outcome
DLTs will be assessed by the review of labs, PE and AEs
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL SNK01
Study Locations (5)
California
- Behavioral Research Specialists, LLC - Glendale
- Syrentis Clinical Research - Santa Ana
- Valiance Clinical Research - Tarzana
Florida
- AdventHealth Research Institute - Orlando
Ontario
- Ottawa Memory Clinic - Ottawa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-11-21 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What NCT06189963 shows while recruiting
NCT06189963 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Moderate Alzheimer Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06189963 lists 5 locations in 3 states (California, Florida, Ontario).
Frequently Asked Questions
What is clinical trial NCT06189963 about?
NCT06189963 is a clinical study titled "Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease". The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion 2. Can SNK01 administration improve cognitive asse...
What is the current status of trial NCT06189963?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-11-21. Estimated completion is 2026-06.
What conditions does trial NCT06189963 study?
This clinical trial studies the following conditions: Moderate Alzheimer Disease.
What interventions are being tested in trial NCT06189963?
The interventions under investigation include: Placebo (OTHER), SNK01 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06189963?
This trial is sponsored by NKGen Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06189963 being conducted?
This trial has 5 study locations across California, Florida, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06189963's enrollment target sits among peer trials
36 1211th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI